Form 4 for ALNY ALNYLAM PHARMACEUTICALS, INC.
Accepted 2024-08-14 00:00:00 ET · period of report 2024-08-12 · accession 0001735276-24-000083 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-08-14 | 2024-08-12 | ALNY | Fitzgerald Kevin Joseph | CSO, EVP, Head of Research | S - Sale+OE | $270.99 | -22.0K | 13.0K | -63% | -$5.97M |
| DM | 2024-08-14 | 2024-08-12 | ALNY | Fitzgerald Kevin Joseph | CSO, EVP, Head of Research | M - OptEx | $89.09 | +20.7K | 34.9K | +146% | +$1.85M |
| DM | 2024-08-14 | 2024-08-12 | ALNY | Fitzgerald Kevin Joseph | CSO, EVP, Head of Research | M - OptEx | $0.00 | -20.7K | 2,192 | -90% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-08-12 | S | D | 9,662 | $270.17 | 23,823 | D | — | — | (F3) The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $269.90 to $270.87. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| 2 | Common | Common Stock | 2024-08-12 | S | D | 5,736 | $271.32 | 18,087 | D | — | — | (F4) The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $271.02 to $271.99. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| 3 | Common | Common Stock | 2024-08-12 | S | D | 3,913 | $272.43 | 14,174 | D | — | — | (F5) The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $272.23 to $272.99. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| 4 | Common | Common Stock | 2024-08-12 | S | D | 1,421 | $268.66 | 33,485 | D | — | — | (F2) The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $268.53 to $269.52. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| 5 | Common | Common Stock | 2024-08-12 | S | D | 135 | $274.65 | 12,881 | D | — | — | |
| 6 | Common | Common Stock | 2024-08-12 | M | A | 6,667 | $97.72 | 20,848 | D | — | — | |
| 7 | Common | Common Stock | 2024-08-12 | M | A | 14,058 | $85.00 | 34,906 | D | — | — | |
| 8 | Common | Common Stock | 2024-08-12 | S | D | 1,158 | $273.73 | 13,016 | D | — | — | (F6) The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $273.32 to $274.01. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| 9 | Derivative | Stock Option (right to buy) | 2024-08-12 | M | D | 6,667 | $0.00 | 0 | D | $97.72 · — to 2025-12-07 | 6,667 Common Stock | (F9) This stock option was fully vested and exercisable as of December 7, 2015. |
| 10 | Derivative | Stock Option (right to buy) | 2024-08-12 | M | D | 14,058 | $0.00 | 2,192 | D | $85.00 · — to 2029-02-28 | 14,058 Common Stock | (F8) This stock option was fully vested and exercisable as of February 28, 2023. |